Acrivon Therapeutics (ACRV) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 17, 2026, to be held virtually for shareholders of record as of April 23, 2026.

• Key items include election of Class I directors, ratification of the external auditor, and approval of an amended equity incentive plan.

• Supplement adds Proposal 3 to increase shares under the 2022 Equity Incentive Plan by 3,000,000 and amends the evergreen provision.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class I director nominees for three-year terms.

• Proposal to ratify PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Proposal 3 seeks approval to amend and restate the 2022 Equity Incentive Plan, increasing authorized shares and updating the evergreen provision.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board and management emphasize the need for competitive equity compensation to attract and retain talent in the biopharmaceutical sector.

• Approximately 75 employees and six non-employee directors are eligible to participate in the amended plan.